The most complex computer in the world is not made of microchips – it’s sitting right inside your head. Although the fastest supercomputers rival the human brain for raw computational power, nothing ...

At other times, stepping into the non-HD world allowed them to rest, recover, and reconnect with who they were, beyond the ...

This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial. The results of a clinical trial, called VIBRANT-HD, investigating an oral ...

The sequence pattern matters: Interruptions or “hitches” and loss of these within the C-A-G repeat and C-C-G repeat stretches play a major role as to when symptoms start with loss of interruptions ...

For many people raised in families affected by Huntington’s disease (HD), childhood isn’t just about scraped knees and schoolbooks. It can also mean living with uncertainty, emotional turbulence, and ...

INGREZZA is the trade name of valbenazine, a drug developed by the company Neurocrine Biosciences. It works similarly to tetrabenazine and deutetrabenazine (Austedo), drugs commonly prescribed to help ...

For those who were following the live tweets from HDBuzz about the CHDI HD Therapeutics Conference or tuned in to the HDSA Convention, we may have caught your attention with the new HD staging system.

A new study led by researchers from University College London has helped uncover some of the earliest changes that happen in people with the gene for Huntington’s disease (HD), long before obvious ...

Multiple new studies have identified what may be the most important new fact about the genetics of Huntington’s disease since the gene was discovered in 1993. At least two research groups around the ...

This week, we heard an update from Roche about their huntingtin-lowering therapy, tominersen, currently being tested in the GENERATION HD2 trial. An independent data monitoring committee (iDMC) that ...

DNA-based drugs called antisense oligonucleotides, or ASOs, are now in multiple clinical trials in Huntington’s disease, aiming to lower production of the harmful mutant huntingtin protein in the ...

AMT-130 is a huntingtin-lowering treatment, because it seeks to reduce production of the harmful mutant huntingtin protein, which is harmful to neurons and is the cause of Huntington’s disease. A ...